212 related articles for article (PubMed ID: 21310077)
1. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Trachtman H; Vento S; Gipson D; Wickman L; Gassman J; Joy M; Savin V; Somers M; Pinsk M; Greene T
BMC Nephrol; 2011 Feb; 12():8. PubMed ID: 21310077
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
4. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.
Peyser A; Machardy N; Tarapore F; Machardy J; Powell L; Gipson DS; Savin V; Pan C; Kump T; Vento S; Trachtman H
BMC Nephrol; 2010 Jan; 11():2. PubMed ID: 20113498
[TBL] [Abstract][Full Text] [Related]
5. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
6. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.
Joy MS; Gipson DS; Dike M; Powell L; Thompson A; Vento S; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Clin J Am Soc Nephrol; 2009 Jan; 4(1):39-47. PubMed ID: 19073787
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Usta M; Ersoy A; Dilek K; Ozdemir B; Yavuz M; Güllülü M; Yurtkuran M
J Intern Med; 2003 Mar; 253(3):329-34. PubMed ID: 12603500
[TBL] [Abstract][Full Text] [Related]
9. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience.
Hubsch H; Montané B; Abitbol C; Chandar J; Shariatmadar S; Ciancio G; Burke G; Miller J; Strauss J; Zilleruelo G
Pediatr Nephrol; 2005 Feb; 20(2):210-6. PubMed ID: 15605284
[TBL] [Abstract][Full Text] [Related]
10. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy.
Kanbay M; Sekuk H; Yilmaz U; Gur G; Boyacioglu S
Dig Dis; 2005; 23(1):92-4. PubMed ID: 15920330
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
Han KH; Kim SH
Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
[TBL] [Abstract][Full Text] [Related]
12. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Freiberger V; Amann K; Heemann U; Frank H
Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068
[TBL] [Abstract][Full Text] [Related]
13. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
Ramsay LE; Yeo WW;
J Hypertens Suppl; 1995 Jul; 13(1):S73-6. PubMed ID: 18800460
[TBL] [Abstract][Full Text] [Related]
14. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis.
El-Reshaid K; El-Reshaid W; Madda J
Ren Fail; 2005; 27(5):523-30. PubMed ID: 16152989
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
Siligato R; Cernaro V; Nardi C; De Gregorio F; Gembillo G; Costantino G; Conti G; Buemi M; Santoro D
Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
[TBL] [Abstract][Full Text] [Related]
16. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Trachtman H; Nelson P; Adler S; Campbell KN; Chaudhuri A; Derebail VK; Gambaro G; Gesualdo L; Gipson DS; Hogan J; Lieberman K; Marder B; Meyers KE; Mustafa E; Radhakrishnan J; Srivastava T; Stepanians M; Tesar V; Zhdanova O; Komers R;
J Am Soc Nephrol; 2018 Nov; 29(11):2745-2754. PubMed ID: 30361325
[TBL] [Abstract][Full Text] [Related]
17. The treatment of idiopathic focal segmental glomerulosclerosis in adults.
Hogan J; Radhakrishnan J
Adv Chronic Kidney Dis; 2014 Sep; 21(5):434-41. PubMed ID: 25168833
[TBL] [Abstract][Full Text] [Related]
18. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
[TBL] [Abstract][Full Text] [Related]
19. Treatment of FSGS in Children.
Sethna CB; Gipson DS
Adv Chronic Kidney Dis; 2014 Mar; 21(2):194-9. PubMed ID: 24602468
[TBL] [Abstract][Full Text] [Related]
20. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
